FDA Advisors Weigh In on Cancer Early-Detection Blood Test

A panel of U.S. Food and Drug Administration (FDA) advisors convened on June 5, 2024, to deliberate on the merits and potential drawbacks of a new blood test aimed at detecting multiple types of cancer in their early stages. The test, developed by Guardant Health, is designed to identify circulating tumor DNA (ctDNA) shed by cancerous cells into the bloodstream, offering a less invasive alternative to traditional screening methods. This discussion is critical as it informs the FDA's decision-making process regarding the approval and widespread adoption of such groundbreaking diagnostic tools.

The advisory committee's role is to provide expert recommendations to the FDA, which ultimately holds the authority to approve medical devices and treatments. The panel's deliberations focused on several key areas, including the test's analytical validity, clinical validity, and clinical utility. Analytical validity refers to the test's ability to accurately and reliably detect ctDNA. Clinical validity assesses how well the test identifies individuals with cancer and correctly distinguishes them from those without cancer. Clinical utility examines whether the test's results can lead to improved patient outcomes, such as earlier diagnosis, more effective treatment selection, and ultimately, reduced cancer mortality.

Guardant Health's test, known as the Shield test, has undergone extensive clinical trials. The company presented data from studies involving thousands of participants, highlighting the test's performance in identifying various cancer types, including lung, colorectal, and breast cancer, often before symptoms manifest. The advisors scrutinized this data, questioning the specificity and sensitivity of the test, particularly in asymptomatic individuals where the risk of false positives could lead to unnecessary anxiety, invasive follow-up procedures, and associated costs. They also considered the potential for false negatives, which could provide a false sense of security and delay necessary medical attention.

The discussion also encompassed the practical implementation of the test in clinical settings. This includes how the test results would be integrated into existing cancer screening paradigms, the necessary infrastructure for widespread testing, and the economic implications for healthcare systems and patients. The advisors explored the potential impact on healthcare disparities and the need for clear guidelines on who should undergo such testing and at what frequency. The committee's feedback will be instrumental in shaping the regulatory pathway for Guardant Health's Shield test and similar multi-cancer early detection (MCED) technologies, which hold significant promise for transforming cancer care by enabling earlier intervention and improving survival rates.